What is it about?

Bevacizumab in Recurrent High-Grade Gliomas: A Canadian Retrospective Study. àA single-center retrospective review of patients started on bevacizumab for rGBM from 2012 to 2015 was performed. Patient demographics, tumor characteristics, treatment regimen, and dates of clinical progression and death were collected. Overall survival (OS) and progression-free survival (PFS) were used as clinical outcomes and estimates. Radiological response was assessed using modified Response Assessment in Neuro-Oncology criteria.

Featured Image

Why is it important?

Bevacizumab has been used in recurrent glioblastoma (rGBM) since 2010 in Canada. Given its cost, potential toxicities, and unclear efficacy, further studies are required to better define suitable candidates for therapy.

Perspectives

Conclusions: This is the first reported Canadian experience with bevacizumab for rGBM. Our clinical outcomes are consistent with published data from multicenter phase II and III trials on bevacizumab in rGBM. More research is required to determine which subtype(s) of patients with rGBM could benefit from bevacizumab upon recurrence.

Dr Catherine Maurice
University of Toronto

Read the Original

This page is a summary of: Bevacizumab in Recurrent High-Grade Gliomas: A Canadian Retrospective Study, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, November 2017, Cambridge University Press, DOI: 10.1017/cjn.2017.248.
You can read the full text:

Read

Resources

Contributors

The following have contributed to this page